Summit's photorefractive keratectomy (PRK) laser "approvable" in US:
This article was originally published in Clinica
Executive Summary
The US FDA has notified Summit Technology that its excimer laser is approvable for treating photorefractive keratectomy (PRK). When finally approved, the laser system will be used to perform laser vision correction of up to 7 diopters using a 6 mm optical zone. PMA for use of the laser system for phototherapeutic keratectomy was approved in the US earlier this year. It is currently the only company with marketing approval for ophthalmic use of excimer lasers in the US. The day after receiving the approvable letter, Summit filed a registration statement with the US Securities and Exchange Commission for the issue of 2,200,000 shares of common stock.